Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Raw Materials: 2015-2025

Historic Raw Materials for Amphastar Pharmaceuticals (AMPH) over the last 9 years, with Sep 2025 value amounting to $105.8 million.

  • Amphastar Pharmaceuticals' Raw Materials rose 74.70% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 74.70%. This contributed to the annual value of $81.5 million for FY2024, which is 62.76% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Raw Materials stood at $105.8 million, which was down 0.74% from $106.5 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Raw Materials' 5-year high stood at $106.5 million during Q2 2025, with a 5-year trough of $40.4 million in Q1 2022.
  • For the 3-year period, Amphastar Pharmaceuticals' Raw Materials averaged around $69.4 million, with its median value being $56.4 million (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' Raw Materials declined by 20.63% in 2021 and then soared by 100.84% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Raw Materials (Quarterly) stood at $41.9 million in 2021, then climbed by 13.75% to $47.6 million in 2022, then grew by 5.20% to $50.1 million in 2023, then soared by 62.76% to $81.5 million in 2024, then spiked by 74.70% to $105.8 million in 2025.
  • Its last three reported values are $105.8 million in Q3 2025, $106.5 million for Q2 2025, and $103.3 million during Q1 2025.